StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)

Close on Nov 18, 2026Market cap $10.06MP/E –Yield –

TScan Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

TScan Therapeutics's price to book ratio was 0.3× on Nov 11, 2026, against 1.0× a year earlier. Over the last 4 years it ranged from 0.2× to 5.8×, with a median of 1.0×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.3×−0.5
2025Dec 31, 20250.9×−0.5
2024Dec 31, 20241.4×−0.2
2023Dec 29, 20231.6×+1.5
2022Jan 31, 20220.2×+0.0
2021Dec 31, 20210.2×–

More TScan Therapeutics figures

See a number that looks wrong?